|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:awards
|
Best Research Company 2021
|
|
gptkbp:biomarker_research
|
gptkb:Oncology
|
|
gptkbp:ceo
|
gptkb:Dr._Max_Mustermann
|
|
gptkbp:clinical_expertise
|
oncologists
|
|
gptkbp:clinical_outcomes
|
improved survival rates
|
|
gptkbp:clinical_research
|
Phase II trials
|
|
gptkbp:clinical_trial
|
gptkb:Berlin
ongoing
Phase III
Phase I
published in journals
|
|
gptkbp:clinical_trials_data
|
analyzed for efficacy
|
|
gptkbp:clinical_trials_participation
|
patient volunteers
|
|
gptkbp:collaboration
|
pharmaceutical companies
|
|
gptkbp:collaborations
|
gptkb:Max_Planck_Institute
gptkb:local_universities
gptkb:international_partners
healthcare providers
local hospitals
government health agencies
NCI
international cancer organizations
cancer treatment centers
biomedical research institutes
|
|
gptkbp:collaborative_projects
|
gptkb:European_Cancer_Consortium
|
|
gptkbp:community_events
|
fundraising for cancer research
|
|
gptkbp:community_involvement
|
cancer awareness programs
|
|
gptkbp:conference
|
Annual Cancer Research Conference
presentations on research findings
|
|
gptkbp:employees
|
50
|
|
gptkbp:focus
|
cancer research
|
|
gptkbp:focus_area
|
gptkb:immunotherapy
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:funding
|
10 million euros
|
|
gptkbp:grants
|
3 million euros
|
|
gptkbp:headquarters
|
gptkb:Berlin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Krebsforschung Gmb H
|
|
gptkbp:impact
|
global cancer research community
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:initiatives
|
early detection
cancer prevention
|
|
gptkbp:invention
|
gptkb:5
|
|
gptkbp:investment
|
biomarker discovery
|
|
gptkbp:location
|
gptkb:Germany
|
|
gptkbp:partnership
|
gptkb:University_of_Berlin
biotech firms
|
|
gptkbp:patient_engagement
|
support groups
|
|
gptkbp:patient_outcomes
|
quality of life improvements
|
|
gptkbp:patient_recruitment
|
clinical trials
|
|
gptkbp:patient_support_programs
|
cancer survivors
|
|
gptkbp:publication
|
gptkb:Journal_of_Cancer_Research
20 per year
|
|
gptkbp:research
|
translational medicine
|
|
gptkbp:research_areas
|
oncology
precision medicine
|
|
gptkbp:research_focus
|
gptkb:Oncology
targeted therapies
|
|
gptkbp:research_funding_agency
|
gptkb:German_Research_Foundation
|
|
gptkbp:research_funding_sources
|
government grants
|
|
gptkbp:research_innovation
|
novel therapies
|
|
gptkbp:research_interest
|
2 million euros
|
|
gptkbp:research_outcomes
|
new treatment protocols
|
|
gptkbp:research_partnerships
|
pharmaceutical research companies
|
|
gptkbp:research_team
|
30 scientists
|
|
gptkbp:revenue
|
5 million euros
|
|
gptkbp:scientific_advisory_board
|
experts in oncology
|
|
gptkbp:subsidiary
|
gptkb:Krebsforschung_Innovations_Gmb_H
|
|
gptkbp:technology
|
genomic sequencing
|
|
gptkbp:website
|
www.krebsforschung-gmbh.de
|
|
gptkbp:bfsParent
|
gptkb:Evotec_AG
|
|
gptkbp:bfsLayer
|
6
|